Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXACT-HF: Allopurinol in Hyperuricemic Heart Failure
NCT00987415Phase 2Completed
- Sponsor
- Duke University
- Start
- May 2010
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of allopurinol in heart failure (HF) and hyperuricemia (2 arms), sponsored by Duke University. Primary endpoint: Composite Clinical Endpoint at 24 weeks. Started May 2010; status: completed.
02
Drugs
allopurinol
03
Conditions
heart failure (HF)hyperuricemia
Beyond the preview
Go deeper on NCT00987415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00987415.